<DOC>
	<DOCNO>NCT01744236</DOCNO>
	<brief_summary>The aim study detail ( mechanisms underlie ) action GLP-1 receptor agonists DPP-4 inhibitor cardiovascular , renal gastrointestinal system patient Type 2 Diabetes Mellitus .</brief_summary>
	<brief_title>SAFEGUARD : Pleiotropic Effects Incretin Based Therapies</brief_title>
	<detailed_description>GLP-1 receptor present organ system human body , pharmacological intervention enhance GLP-1 activity may influence function organ . The use GLP-1 receptor agonist ( GLP-1RA ) DPP-4 inhibitor ( DPP-4i ) associate increased heart rate , acute pancreatitis acute renal failure . To date , study human detail effect drug organ system , biological process underlie mechanism , could explain association , lack . Therefore , part EU-FP7 SAFEGUARD program , present study aim detail ( mechanisms underlie ) action GLP-1RA DPP-4i cardiovascular , renal gastrointestinal system healthy obese subject patient T2DM . In main study , sixty patient type 2 diabetes undergo two intervention within protocol order ass change outcome parameter : - acute study = acute infusion exenatide placebo ( assess cardiovascular renal effect ) - long-term study = 12 week treatment liraglutide , sitagliptin placebo ( assess cardiovascular , renal gastrointestinal effect ) In substudy ( term 'acute MRI study ' ) , twelve patient type 2 diabetes undergo additional acute intervention study exenatide ( assess pancreatic effect ) In substudy ( term 'pilot-study ' ) , ten healthy obese subject undergo similar acute study like patient type 2 diabetes ( assess cardiovascular renal effect ) . Moreover , healthy subject , effect exenatide L-NMMA infusion assess .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
	<criteria>Age 35 75 year . Females must postmenopausal ( menses &gt; 1 year ) . Type 2 diabetes ( HbA1c 6.59 % DCCT 4875 mmol/mol IFCC ) , treat stable dose oral antihyperglycemic agent ( either metformin alone , SU alone combination metformin SU ) least 3 month prior inclusion . BMI 25 40 kg/m2 Caucasian Signed inform consent GFR &lt; 60 mL/min/1.73m2 Current / chronic use follow medication : thiazolidinediones , GLP1RA , DPP4i , glucocorticoid , NSAIDs , insulin , antimicrobial agent , chemotherapeutics immune suppressant . Subjects diuretic exclude drug ( e.g . hydrochlorothiazide ) stop duration study . History actual pancreatic disease impair pancreatic exocrine function Active liver disease History actual malignancy ( exception basal cell carcinoma ) Current urinary tract infection active nephritis Recent ( &lt; 6 month ) history cardiovascular disease , include acute coronary syndrome , stroke , transient ischemic neurologic disorder chronic heart failure ( New York Heart Association grade IIIV ) Current atrial fibrillation Chronic infectious autoimmune disease Substance and/or alcohol abuse History allergy/hypersensitivity test agent Complaints compatible establish gastroparesis and/or neurogenic bladder Any condition recognize contraindication use GLP1RA DPP4i , list respective SPCs History actual ( severe ) mental illness Inability understand study protocol and/or inability give inform consent History claustrophobia presence metal objects/implants ( MRI protocol ) For precede Pilot study , include : Males Age 18 50 year BMI 25 40 kg/m2 Caucasian The exclusion criterion precede pilot study similar exclusion criterion main study , addition : Subjects fast plasma glucose ≥5.6 mmol/L , 2hour glucose ≥7.8 mmol/L 75grams oral glucose tolerance test , HbA1c ≥6.5 % Subjects use kind medication</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>GLP-1 Receptor Agonists , DPP-4 inhibitor</keyword>
</DOC>